SCHEMBL4154496

SCHEMBL4154496

CNC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
MAPT P10636 1/20 0.67
POLB P06746 3/20 0.62
ALDH1A1 P00352 3/20 0.62
THRB P10828 1/20 0.62
RECQL P46063 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MEN1 O00255 1/20 0.60
USP2 O75604 1/20 0.60
ALOX15 P16050 1/20 0.60
KMT2A Q03164 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.59
TSHR P16473 1/20 0.59
CASP1 P29466 1/20 0.59
PYGL P06737 1/20 0.58
LMNA P02545 1/20 0.57
FLT1 P17948 3/20 0.56
FLT4 P35916 3/20 0.56
KDR P35968 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29833777 1.00 KDM4E (0.67) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL3787454 0.86 ALDH1A1 (0.50) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL7987535 0.84 ALDH1A1 (0.67) KDM4EPOLBALDH1A1MEN1KMT2A
SCHEMBL11419345 0.83 ALDH1A1 (0.77) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL7706279 0.82 HPGD (0.59) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3783986 0.82 PYGL (0.57) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL8318320 0.82 FLT1 (0.59) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL3814303 0.82 P2RX1 (0.53) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL393739 0.82 KDM4E (0.69) KDM4EMAPTPOLBALDH1A1THRB
SCHEMBL6790469 0.82 KDM4E (0.69) KDM4EMAPTPOLBALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606556-B2 TYK-2 inhibitor BEONE MEDICINES I GMBH (CH) 2026-04-21 US disclosed
US-20230159520-A1 TYK-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed
CN-115003667-A TYK-2 inhibitors 百济神州有限公司 2022-09-02 CN disclosed
US-9556129-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2017-01-31 US disclosed
US-9556129-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2017-01-31 US disclosed
US-20150336902-A1 Phosphatidylcholine Transfer Protein Inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2015-11-26 US disclosed
US-20150336902-A1 Phosphatidylcholine Transfer Protein Inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2015-11-26 US disclosed
US-9126938-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-09-08 US disclosed
US-9126938-B2 Phosphatidylcholine transfer protein inhibitors THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-09-08 US disclosed
US-9102645-B2 Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) 2015-08-11 US disclosed
US-4160095-A PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1979-07-03 US disclosed
US-4157441-A PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS THE UPJOHN COMPANY (US) 1979-06-05 US disclosed
US-4151351-A PROSTAGLANDINS, ANTIINFLAMMATORY THE UPJOHN COMPANY (US) 1979-04-24 US disclosed
US-4131738-A 6-Hydroxy-PGE1 compounds THE UPJOHN COMPANY (US) 1978-12-26 US disclosed
US-4128713-A 6,7-Didehydro-PGI1 compounds THE UPJOHN COMPANY (US) 1978-12-05 US disclosed
US-4126744-A PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS THE UPJOHN COMPANY (US) 1978-11-21 US disclosed
US-4112224-A PROSTAGLANDIN THE UPJOHN COMPANY (US) 1978-09-05 US disclosed
US-4109082-A PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS THE UPJOHN COMPANY (US) 1978-08-22 US disclosed
US-4100192-A Inter-phenylene-PG amides THE UPJOHN COMPANY (US) 1978-07-11 US disclosed
US-4097489-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606556-B2 TYK-2 inhibitor TYK2, TXK, JAK1 KDM4E 749/4885MAPT 3485/4885POLB 2084/4885
US-20230159520-A1 TYK-2 INHIBITOR TYK2, IRAK2, PTK2B KDM4E 613/4885MAPT 804/4885POLB 2307/4885
US-20150336902-A1 Phosphatidylcholine Transfer Protein Inhibitors PCTP, LCAT, CETP KDM4E 2751/4885MAPT 781/4885POLB 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.